Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
复制标题
抗PD-1/PD-L1单克隆抗体治疗实体瘤患者的肾毒性：系统综述和荟萃分析。
DOI：
10.1007/s10637-020-01039-5
复制
发表时间：
2021-06
影响因子：
3.4
通讯作者：
Jin J
中科院分区：
文献类型：
--
作者：
Li H;Xu J;Bai Y;Zhang S;Cheng M;Jin J
背景程序性死亡-1（PD-1）和程序性死亡配体1（PD-L1）显著改善了许多患者的癌症治疗。已发现肾脏不良反应是一种重要的并发症，但机制尚不清楚。方法我们检索Embase、PubMed和科克伦图书馆，以确定潜在的合格研究。所有纳入的研究均为随机对照试验（RCT），检查了接受抗PD-1/PD-L1单克隆抗体（mAb）和/或化疗治疗的实体瘤患者。使用相对风险（RR）评估肾毒性事件的风险。结果我们纳入了27项临床试验（15，063例患者）。与化疗相比，抗PD-1/PD-L1单抗治疗各期肾炎的RR显著增加（RR = 2.77，95%CI：1.09-6.99，P = 0.03）。抗PD-1/PD-L1单克隆抗体联合化疗可显著增加各期肾炎的RR（RR = 2.99，95%CI：1.07-8.35，P = 0.04）。所有级别血肌酐升高（RR = 1.88，95% CI：1.24-2.86，P = 0.003）和急性肾损伤（阿基）（RR =3.35，95% CI：1.48-7.60，P = 0.004）的RR也显著增加。结论抗PD-1/PD-L1单抗可显著增加实体瘤患者的肾毒性，尤其是与化疗联合应用时。在应用这些药物时，应注意其肾毒性，以提高疗效。试验注册号和注册日期不适用。在线版本包含补充材料，可通过10.1007/s10637-020-01039-5获得。
Background Programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) have dramatically improved cancer therapy for many patients. Adverse kidney effects have been found to be an important complication but have unclear mechanisms. Methods We searched Embase, PubMed, and the Cochrane Library to identify potential eligible studies. All included studies were randomized controlled trials (RCTs) examining patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies (mAbs) and/or chemotherapy. The relative risk (RR) was used to assess the risk of nephrotoxic events. Results We included 27 clinical trials (15,063 patients). Compared with chemotherapy, the RR of all-grade nephritis was significantly increased with anti-PD-1/PD-L1 mAbs (RR = 2.77, 95% CI: 1.09–6.99, P = 0.03). Furthermore, anti-PD-1/PD-L1 mAbs plus chemotherapy can significantly increase the RR of all-grade nephritis (RR = 2.99, 95% CI: 1.07–8.35, P = 0.04). There was also a significant increase in the RRs of all-grade increased blood creatinine (RR = 1.88, 95% CI: 1.24–2.86, P = 0.003) and acute kidney injury (AKI) (RR =3.35, 95% CI: 1.48–7.60, P = 0.004). Conclusions Anti-PD-1/PD-L1 mAbs can significantly increase nephrotoxicity in patients with solid tumors, especially when combined with chemotherapy. During the application of these drugs, we should remain aware of nephrotoxicity for better efficacy. Trial registration number and date of registration Not applicable. The online version contains supplementary material available at 10.1007/s10637-020-01039-5.
登录
查看更多内容
影响因子：
19.6
作者：
Cortazar FB;Marrone KA;Troxell ML;Ralto KM;Hoenig MP;Brahmer JR;Le DT;Lipson EJ;Glezerman IG;Wolchok J;Cornell LD;Feldman P;Stokes MB;Zapata SA;Hodi FS;Ott PA;Yamashita M;Leaf DE
通讯作者：
Leaf DE
影响因子：
10.9
作者：
Mamlouk, Omar;Selamet, Umut;Abudayyeh, Ala
通讯作者：
Abudayyeh, Ala
影响因子：
2.2
作者：
DerSimonian R;Laird N
通讯作者：
Laird N
IV期或复发性非小细胞肺癌中的一线Nivolumab。
DOI：
10.1056/nejmoa1613493
发表时间：
2017-06-22
期刊：
The New England journal of medicine
影响因子：
--
作者：
Carbone DP;Reck M;Paz-Ares L;Creelan B;Horn L;Steins M;Felip E;van den Heuvel MM;Ciuleanu TE;Badin F;Ready N;Hiltermann TJN;Nair S;Juergens R;Peters S;Minenza E;Wrangle JM;Rodriguez-Abreu D;Borghaei H;Blumenschein GR Jr;Villaruz LC;Havel L;Krejci J;Corral Jaime J;Chang H;Geese WJ;Bhagavatheeswaran P;Chen AC;Socinski MA;CheckMate 026 Investigators
通讯作者：
CheckMate 026 Investigators
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM